What is the 13F Pro Quality Score for OM?

13F Pro ranks Outset Medical, Inc. (OM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OM's current score at https://13fpro.ai/company/OM (free sign-up required for the full ranking).

Which hedge funds own the most OM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of OM include FMR, BML Capital Management,, AQR CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/OM as soon as new 13F filings post.

Where does 13F Pro source OM data?

All Outset Medical, Inc. fundamentals and ownership data come directly from SEC EDGAR. Outset Medical, Inc. files with the SEC under CIK 1484612. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OM in?

Outset Medical, Inc. (OM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OM research updated on 13F Pro?

OM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Outset Medical, Inc.(OM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1484612 OM stock profile & AI dashboard →

13F Pro Quality Score

18.5/100

Rank #2,808 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

19.9/100

Profitability

9.9/100

Balance Sheet

8.3/100

Earnings Quality

33.2/100

Free Cash Flow

11.3/100

Institutional Flow

4.6/100

Revenue Scale

17.9/100

Dilution Risk

13.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why OM Scores 19/100

exact factor attribution · 2026-09-11

OM's composite is driven by earnings growth, held back by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+1.1 pts

72th pct

Earnings quality

-1.7 pts

33th pct

Shareholder dilution

-1.8 pts

13th pct

Institutional flow

-2.3 pts

5th pct

Capital efficiency

-4.2 pts

8th pct

Scale

-4.8 pts

18th pct

Free cash flow

-5.8 pts

11th pct

Profitability

-6.0 pts

10th pct

Revenue growth

-6.0 pts

20th pct

Latest change (2026-08-07): 18 → 21 · ↑ Revenue growth 22→33

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

OM Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Outset Medical, Inc. (OM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OM at 18.5/100 on a 32-signal composite quality model, placing it at rank #2,808 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (4.6) and balance sheet strength (8.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Outset Medical, Inc. reports quarterly revenue of $31.6M, net income of $-18.0M, an operating margin of -49.5%. Top institutional holders of OM by reported 13-F value include FMR, BML Capital Management, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. OM trades on the Nasdaq exchange and files with the SEC under CIK 1484612. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Outset Medical, Inc. directly from SEC EDGAR. Outset Medical, Inc.'s 13F Pro composite quality score has ranged between 15 and 34 since 2021, currently 18.5 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

Revenue

Q2 2026

$31.6M

Net Income

Q2 2026

$-18.0M

Free Cash Flow

Q2 2026

$-9.7M

Operating Margin

Q2 2026

-49.5%

ROIC

Q2 2026

-32.3%

D/E Ratio

Q2 2026

1.01

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+5.1% YoY

$119.5MFY 2025

FY22 $115.4MFY23 $130.4MFY24 $113.7MFY25 $119.5M

Net Income

+36.2% YoY

$-81.7MFY 2025

FY22 $-163.0MFY23 $-172.8MFY24 $-128.0MFY25 $-81.7M

Operating Income

+41.2% YoY

$-66.7MFY 2025

FY22 $-161.0MFY23 $-169.8MFY24 $-113.4MFY25 $-66.7M

EPS (Diluted)

+85.5% YoY

$-5.37FY 2025

FY22 $-3.38FY23 $-52.28FY24 $-36.96FY25 $-5.37

Total Assets

-4.1% YoY

$264.5MFY 2025

FY22 $400.1MFY23 $313.8MFY24 $275.8MFY25 $264.5M

Total Debt

-51.2% YoY

$96.2MFY 2025

FY22 $101.1MFY23 $130.1MFY24 $197.4MFY25 $96.2M

Op. Cash Flow

+60.2% YoY

$-46.3MFY 2025

FY22 $-145.7MFY23 $-131.4MFY24 $-116.3MFY25 $-46.3M

Free Cash Flow

+59.8% YoY

$-47.1MFY 2025

FY22 $-154.1MFY23 $-134.8MFY24 $-117.2MFY25 $-47.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$119.5M +5.1%	$113.7M -12.8%	$130.4M +13.0%	$115.4M +12.4%	$102.6M +105.5%	$49.9M
Net Income	$-81.7M +36.2%	$-128.0M +25.9%	$-172.8M -6.0%	$-163.0M -23.5%	$-131.9M -8.6%	$-121.5M
Operating Income	$-66.7M +41.2%	$-113.4M +33.2%	$-169.8M -5.4%	$-161.0M -23.4%	$-130.5M -11.1%	$-117.5M
EPS (Diluted)	$-5.37 +85.5%	$-36.96 +29.3%	$-52.28 -1446.7%	$-3.38 -17.0%	$-2.89 +40.4%	$-4.85
Total Assets	$264.5M -4.1%	$275.8M -12.1%	$313.8M -21.6%	$400.1M -13.7%	$463.5M +14.8%	$403.8M
Total Debt	$96.2M -51.2%	$197.4M +51.7%	$130.1M +28.7%	$101.1M +218.0%	$31.8M +0.3%	$31.7M
Operating Cash Flow	$-46.3M +60.2%	$-116.3M +11.5%	$-131.4M +9.9%	$-145.7M -11.9%	$-130.3M -31.6%	$-99.0M
Free Cash Flow	$-47.1M +59.8%	$-117.2M +13.1%	$-134.8M +12.5%	$-154.1M -15.5%	$-133.4M -23.4%	$-108.1M

Get alerted when OM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Outset Medical, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OM

FMR LLC
$11.8M2,742,887 sh
BML Capital Management, LLC
$10.9M2,519,701 sh
AQR CAPITAL MANAGEMENT LLC
$4.3M998,961 sh
PERCEPTIVE ADVISORS LLC
$3.6M833,333 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.4M780,134 sh
BANK OF AMERICA CORP /DE/
$2.9M665,847 sh
PFM Health Sciences, LP
$2.5M582,122 sh
Ensign Peak Advisors, Inc
$1.9M434,341 sh
BlackRock, Inc.
$1.8M418,211 sh
Assenagon Asset Management S.A.
$1.5M339,438 sh

Fund	Value	Shares
FMR LLC	$11.8M	2,742,887
BML Capital Management, LLC	$10.9M	2,519,701
AQR CAPITAL MANAGEMENT LLC	$4.3M	998,961
PERCEPTIVE ADVISORS LLC	$3.6M	833,333
VANGUARD CAPITAL MANAGEMENT LLC	$3.4M	780,134
BANK OF AMERICA CORP /DE/	$2.9M	665,847
PFM Health Sciences, LP	$2.5M	582,122
Ensign Peak Advisors, Inc	$1.9M	434,341
BlackRock, Inc.	$1.8M	418,211
Assenagon Asset Management S.A.	$1.5M	339,438

Companies Similar to OM

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MGX

Metagenomi Therapeutics, Inc.

AI score

Very similar · 3 shared holders

Peapod Lane Capital LLC Catalio Capital Management, LP Marquette Asset Management, LLC

KPTI

Karyopharm Therapeutics Inc.

AI score

Similar quality profile · 2 shared holders

Catalio Capital Management, LP C WorldWide Group Holding A/S

TIL

Instil Bio, Inc.

AI score

Similar quality profile · 1 shared holders

BML Capital Management, LLC

NNOX

Nano-X Imaging Ltd.

AI score

Similar quality profile · 1 shared holders

GMT CAPITAL CORP

DCGO

DocGo Inc.

AI score

Similar quality profile · 3 shared holders

Peapod Lane Capital LLC Marquette Asset Management, LLC R Squared Ltd

STXS

Stereotaxis, Inc.

AI score

Similar quality profile · 2 shared holders

GMT CAPITAL CORP R Squared Ltd

LUNG

Pulmonx Corp

AI score

Similar quality profile · 1 shared holders

R Squared Ltd

MXCT

MAXCYTE, INC.

AI score

Similar quality profile · 4 shared holders

Peapod Lane Capital LLC Marquette Asset Management, LLC Catalyst Funds Management Pty Ltd

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OM on your watchlist

Track score changes the day Outset Medical, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OM a good stock to buy?

13F Pro's AI-powered analysis of Outset Medical, Inc. (OM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OM are available on the OM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. OM is classified as a small company.

Which hedge funds own OM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Outset Medical, Inc.'s investment landscape.